Jan Moritz Middeke

Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease

Robert Zeiser, Nicola Polverelli, Ron Ram et al. · New England Journal of Medicine · 2021 · 453 citations · Full text

Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial

Uwe Platzbecker, Jan Moritz Middeke, Katja Sockel et al. · The Lancet Oncology · 2018 · 341 citations

Hematological Malignancy, Oncology, Mixed-phenotype Acute Leukemia +10

Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease

Anke Theil, Sebastian Tuve, Uta Oelschlägel et al. · Cytotherapy · 2015 · 175 citations

Cell Therapy, Transplantation, Autoimmune Disease +12

Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML

Martin Wermke, Sabrina Kraus, Armin Ehninger et al. · Blood · 2021 · 160 citations · Full text

Relapsed/refractory Aml, Automotive Electronics, Engineering +1

<i>CEBPA</i> mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome

Franziska Taube, Julia Annabell Georgi, Michael Krämer et al. · Blood · 2021 · 159 citations · Full text